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Abstract.  44 
DNA methylation and Polycomb are key factors in the establishment of vertebrate 45 
cellular identity and fate. Here we report de novo missense mutations in DNMT3A, 46 
encoding the DNA methyltransferase DNMT3A, that cause microcephalic dwarfism, 47 
a hypocellular disorder of extreme global growth failure. Substitutions in the PWWP 48 
domain abrogate binding to the histone modifications H3K36me2/3, and alter DNA 49 
methylation in patient cells. Polycomb-associated DNA methylation canyons/valleys, 50 
hypomethylated domains encompassing developmental genes, become methylated 51 
with concomitant depletion of H3K27me3 and H3K4me3 bivalent marks. Such de 52 
novo DNA methylation occurs during differentiation of Dnmt3aW326R pluripotent cells 53 
in vitro, and is also evident in Dnmt3aW326R/+ dwarf mice. We therefore propose that 54 
the interaction of the DNMT3A PWWP domain with H3K36me2/3 normally limits 55 
DNA methylation of polycomb-marked regions.  Our findings implicate the interplay 56 
between DNA methylation and polycomb at key developmental regulators as a 57 
determinant of organism size in mammals. 58 
  59 
Introduction 60 
Microcephalic dwarfism represents a group of conditions of profound size reduction 61 
in humans. These single gene disorders are distinguished from other forms of 62 
dwarfism by severity and morphology. Growth is globally impaired pre- and post-63 
natally with proportionate scaling1. Reduced brain size in microcephalic dwarfism 64 
differentiates it from other forms of dwarfism and reflects an early developmental 65 
origin. We and others have discovered many microcephalic dwarfism genes to 66 
encode essential components of the cell cycle machinery, including replication 67 
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licensing components2-5 and key mitotic proteins6-8.  Mutations in these genes result 68 
in reduced cell number and consequently organism size1.  69 
 70 
As cell number is also the major determinant of size differences between mammals9  71 
and the molecular basis for many microcephalic dwarfism patients still remains to be 72 
defined, we performed whole-exome sequencing (WES) to identify novel genetic 73 
causes and inform understanding of size regulation.  74 
 75 
Results 76 
De novo mutations in DNMT3A causes microcephalic dwarfism 77 
WES trio analysis of a microcephalic dwarfism family identified a de novo DNMT3A 78 
heterozygous mutation in the proband (NM_175629.2:c.988T>C, Fig. 1a,b and 79 
Supplementary Table 1). This resulted in the replacement of a tryptophan residue 80 
with an arginine at codon 330 (p.W330R) in the highly conserved PWWP domain of 81 
this DNA methyltransferase (Fig. 1c). NGS sequencing of our patient cohort then 82 
identified an unrelated patient with the same heterozygous de novo missense variant 83 
in DNMT3A (c.988T>C p.W330R, Supplementary Table 1). This substitution was not 84 
present in the GnomAD10 database suggesting it to be absent from the general 85 
population. The two individuals were phenotypically similar, exhibiting significant, 86 
proportionate reduction in head circumference and height (Supplementary Note, 87 
clinical synopsis). The shared clinical phenotype, in conjunction with independent de 88 
novo mutation of the same highly conserved residue, led us to conclude that these 89 
were pathogenic mutations. More recently, we ascertained a further microcephalic 90 
dwarfism patient with a de novo mutation in an adjacent codon (c.997G>A; 91 
p.D333N). Notably, the growth parameters of all three patients contrast markedly 92 
with those of previously reported patients with de novo germline missense and 93 
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truncating loss of function DNMT3A mutations11,12, who have the reciprocal 94 
phenotype of macrocephalic overgrowth Tatton-Brown Rahman syndrome (TBRS, 95 
Fig. 1d). As DNMT3A haploinsufficiency causes overgrowth13, this suggested the 96 
c.988T>C and c.997G>A mutations to be genetic ‘gain of function’ mutations. 97 
 98 
DNMT3AW330R is stably expressed 99 
To model the consequences of the W330R substitution on DNMT3A stability we 100 
engineered mouse embryonic stem cells (mESCs) homozygous and heterozygous 101 
for the orthologous mutation, W326R, using CRISPR/Cas9-mediated homology-102 
directed repair14. Immunoblotting of these lines established that the Dnmt3aW326R 103 
protein is stably expressed. In contrast, mESCs homozygous for the overgrowth 104 
PWWP mutations W293del and I306N (W297del and I310N in human, respectively), 105 
had markedly reduced Dnmt3a levels (Fig. 2a). We also generated recombinant 106 
wildtype and mutant human DNMT3A PWWP domains as GST-fusion proteins. 107 
While we were able to efficiently express and purify PWWPWT and PWWPW330R 108 
proteins, the overgrowth PWWPW297del and PWWPI310N proteins did not yield stable 109 
protein (Supplementary Fig. 1a). This supports the notion that the W330R mutation 110 
alters PWWP function, distinct from that of PWWP overgrowth mutations, which 111 
interfere with protein stability.  112 
 113 
The DNMT3AW330R substitution impairs binding to methylated H3K36 114 
The PWWP-domain of DNMT3A binds post-translationally modified histone H3 that 115 
has been tri-methylated at Lysine 36 (H3K36me3)15,16. Tryptophan 330 is one of 116 
three aromatic amino acids that along with an aspartate residue (Asp333), form an 117 
aromatic cage around the methylated lysine17,18 (Fig. 2b). Structural modelling of the 118 
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DNMT3AW330R substitution predicts that the arginine substitution substantially 119 
disrupts this interaction (interaction destabilization: 11.8 kcal/mol).  120 
 121 
To test this experimentally, we performed pulldown experiments of histone tail 122 
peptides using GST-PWWP fusion proteins. Whereas PWWPWT interacted with an 123 
H3K36me3 modified histone-tail peptide but not the corresponding unmodified 124 
peptide, we did not detect an interaction of the mutant PWWPW330R with H3K36me3 125 
(Fig. 2c,d). To confirm this and assess whether the W330R substitution conferred an 126 
alternative binding specificity on the PWWP domain, a peptide array containing 384 127 
unique and combinatorial histone tail modifications was probed with recombinant 128 
protein. PWWPWT bound strongly to H3K36me3 and H3K36me2 as previously 129 
reported15,19. However, under the same experimental conditions, PWWPW330R did not 130 
bind to any histone modification represented on the array (Fig. 2e and 131 
Supplementary Fig. 1b). 132 
  133 
The second mutation, p.D333N, is located at the aspartate residue that forms part of 134 
the cage surrounding H3K36me2/3 (Fig. 2b). As substitution of this residue is known 135 
to abrogate H3K36me2/3 binding15, we conclude that both the W330R and D333N 136 
substitutions are likely to impair DNMT3A’s binding of methylated H3K36.  137 
 138 
As the N-terminal and ADD-domains of DNMT3A also mediate chromatin 139 
interactions20,21, this suggested that DNMT3AW330R and DNMT3AD333N proteins would 140 
have altered chromatin-binding specificity, which in turn could modify the pattern of 141 
DNA methylation in patient cells. 142 
 143 
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Increased DNA Methylation occurs at key developmental genes in patient cells 144 
We therefore assessed the genome-wide distribution of DNA methylation in patient-145 
derived fibroblasts using Illumina Infinium MethylationEPIC beadchips. Unsupervised 146 
hierarchical clustering established that dermal primary fibroblasts from 147 
DNMT3AW330R/+ microcephalic dwarfism patients had similar DNA methylation 148 
profiles, significantly distinct from those of healthy subjects (Fig. 3a, p<0.001 for 149 
each group). 1878 differentially methylated regions (DMRs) were common to both 150 
patients (Fig. 3b and Supplementary Fig. 2). Consistent with altered genomic 151 
targeting of DNMT3AW330R, the majority of DMRs were hypermethylated relative to 152 
controls (n=1140, Fig. 3b,c and Supplementary Table 2). Notably, the same regions 153 
of increased DNA methylation were also present in DNMT3AW330R/+ patient 154 
peripheral blood leukocytes (PBLs) indicating this to be a reproducible signature and 155 
not a consequence of in vitro culture22 (Fig. 3b,c). Furthermore, the same 156 
hypermethylated DMRs were also evident in patient P3’s PBLs (Supplementary Fig. 157 
3). In contrast, DMRs hypomethylated in fibroblasts were not observed in patient 158 
PBLs (n=738; Supplementary Fig. 2a,b, Supplementary Fig. 3b,c and 159 
Supplementary Table 3). DNMT3AW330R hypermethylated DMRs were not evident in 160 
DNMT3A overgrowth patient PBLs, (Fig. 3b,c), and were also absent from 161 
pericentrin (PCNT) null patient fibroblasts indicating they were not a general 162 
consequence of microcephalic dwarfism (Supplementary Fig. 2c).   163 
 164 
Gene ontology analysis for the genes located closest to the hypermethylated DMRs 165 
demonstrated a striking association with transcription factors and developmental 166 
processes (Fig. 3d and Supplementary Table 4). Notably multiple Hox, lineage-167 
specific transcription factors and morphogen genes were evident in the DMR gene 168 
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list (Fig. 3e). Visual inspection of the DMRs established these regions to contain 169 
CpG islands (CGIs) and encompass genomic regions surrounding these 170 
developmental genes (Fig. 3f).  171 
 172 
Hypermethylation of Polycomb-marked DNA methylation valleys in patient 173 
cells 174 
To understand the genomic context of the hypermethylated DMRs, we investigated 175 
their chromatin state by intersecting the DMRs with existing ChromHMM annotations 176 
for normal human lung fibroblasts (NHLF)23. The DMRs were significantly enriched 177 
for ‘Poised-Promoter’ and ‘Polycomb-Repressed’ ChromHMM categories (Fig. 4a), 178 
both of which are associated with Polycomb repressive complexes (PRCs). To 179 
directly address if these hypermethylated DMRs were Polycomb-marked regions in 180 
dermal primary fibroblasts, we next performed ChIP-seq for H3K27me3, the 181 
epigenetic signature of the Polycomb repressive complex 2 (PRC2)24,25. Significant 182 
enrichment for control fibroblast H3K27me3 peaks was seen at DMR sites (P < 183 
2.2x10-16, Fig. 4b-d) confirming them to be normally marked by H3K27me3. 184 
 185 
Notably the regions of increased DNA methylation in patient cells were not confined 186 
to CGIs and often extended over tens of kilobases of genomic sequence (Fig. 3f). 187 
Their extent and location were reminiscent of ordinarily hypomethylated domains, 188 
that have been termed ‘DNA methylation valleys’ (DMVs)26,27, ‘DNA methylated 189 
canyons’28 or ‘broad non-methylated islands’29. These have been demonstrated to 190 
be evolutionary conserved regions, often associated with Polycomb-regulated 191 
developmental genes. Subsequent analysis confirmed a significant overlap between 192 
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genes within reported DMVs26 and genes associated with DNMT3AW330R/+ 193 
hypermethylated DMRs (P = 8.3x10-170, Fig 4e).  194 
 195 
Comparison of H3K27me3-marked DMVs in control fibroblasts with those lacking 196 
H3K27me3, established that the polycomb-associated DMVs were specifically 197 
hypermethylated in patients (P = 9.6x10-83, Fig. 4f-h). Subsequent H3K4me3 ChIP-198 
seq showed that hypermethylated DMVs also contained H3K4me3 peaks (Fig. 4f), 199 
consistent with ChromHMM ‘poised-promoter’ predictions (Fig. 4a). DMVs without 200 
Polycomb marks exhibited higher levels of H3K4me3 (Fig. 4 g,i), consistent with 201 
transcriptionally active loci.   202 
 203 
In DNMT3AW330R/+ patient fibroblasts, H3K27me3 levels were reduced at 204 
hypermethylated DMRs and H3K27me3 marked DMVs (Fig. 4f,g, Supplementary 205 
Fig. 4a-f). However,  levels of the H3K27me3 methyltransferase EZH2 were normal 206 
in patient fibroblasts, and total cellular levels of H3K27me3-marked histones were 207 
unchanged when assessed by mass-spectroscopy (Supplementary Fig. 4g-i). 208 
Therefore, reduction in H3K27me3 was likely the result of DNMT3A-mediated DNA 209 
methylation inhibiting PRC2 binding/activity30,31. H3K4me3 levels were also reduced 210 
at hypermethylated DMRs and H3K27me3 marked DMVs (Supplementary Fig. 5a-e), 211 
significantly more than at other H3K4me3 peaks in the genome, consistent also with 212 
this reduction being a secondary consequence of DNA hypermethylation.    213 
 214 
We therefore concluded that the W330R mutation is associated with 215 
hypermethylation of Polycomb-marked DMVs in patient cells, impacting on bivalent 216 
histone marks and modifying the chromatin state at key developmental regulators.  217 
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 218 
H3K36me3 and H3K27me3 histone modifications are usually mutually exclusive32,33, 219 
and strongly anti-correlated genome-wide34. To confirm this was also the case for 220 
DMRs and DMVs we performed H3K36me3 ChIP Rx-seq, and indeed few 221 
H3K36me3 ChIP-seq reads were present in DMVs in control and patient cells, with 222 
no enrichment over ChIP input seen  (Supplementary Fig. 6a,b). Furthermore, 223 
hypermethylated DMRs in both control and patient fibroblasts were substantially 224 
depleted for H3K36me3 ChIP-seq peaks, when compared to all Infinium array probe 225 
sites (Supplementary Fig. 6c).  226 
 227 
Hypermethylation at Polycomb marked loci occurs upon differentiation of 228 
DNMT3AW326R pluripotent stem cells 229 
As large scale de novo DNA methylation occurs during early embryogenesis prior to 230 
implantation35, we reasoned that the increased methylation detected in patient 231 
fibroblasts and leukocytes was likely to have developmental origins. We addressed 232 
this possibility using the previously generated Dnmt3aW326R mES cell lines, 233 
containing the W330R-orthologous murine mutation (Fig. 2a). However, bisulfite 234 
sequencing of the promoter CpG islands of Hoxc13, Sox1 and Foxa1 (loci we had 235 
established to have increased methylation in patient cells), demonstrated similar low 236 
levels of DNA methylation in wild-type, DNMT3AW326R/+ and DNMT3AW326R/W326R ES 237 
cells (Fig. 5a and Supplementary Fig. 7a,b). Nevertheless, upon differentiation to 238 
embryoid bodies (EBs), DNA hypermethylation became evident in DNMT3AW326R/+ 239 
and DNMT3AW326R/W326R cells relative to controls (Fig. 5b). To exclude skewing of 240 
lineage fate in EBs as a confounding explanation for altered methylation, directed 241 
differentiation of mESCs to neural progenitor cells (NPCs)36 was also performed. 242 
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This also demonstrated increased methylation in DNMT3AW326R cells (Fig. 5c). 243 
Furthermore, Reduced Representation Bisulfite Sequencing (RRBS)37 established 244 
that such methylation occurred at many Polycomb-marked loci in neurally-245 
differentiated cells (Fig. 5d,e). 342 hypermethylated DMRs were detected in 246 
DNMT3AW326R/W326R cells relative to wild-type controls (Supplementary Table 5). 247 
These regions were significantly enriched for H3K27me3 ChIP-seq peaks derived 248 
from a wildtype neural-progenitor differentiation dataset38 (P < 2.2x10-16, Fig. 5e). As 249 
well, 105 of 207 DMR-associated genes overlapped orthologous gene loci for 250 
hypermethylated patient fibroblast DMRs (P = 1.7x10-71 Fisher’s exact test, Fig. 5f). 251 
Therefore, we conclude that the W326R substitution causes methylation at 252 
Polycomb-marked developmental genes from early stages of cell fate specification 253 
and differentiation in vitro.  254 
 255 
Neurogenic gene expression bias in Dnmt3aW326R NPCs  256 
To understand the transcriptional consequences of DMR hypermethylation, we next 257 
performed RNA-seq on Dnmt3aW326R/W326R NPCs and DNMT3AW330R/+ fibroblasts. 258 
We found a significant downregulation of transcription of genes associated with 259 
hypermethylated DMRs, whereas transcript levels at hypomethylated DMRs were 260 
unchanged (Fig. 5g and Supplementary Fig. 8a-c). We reasoned that many of the 261 
DMR/DMV-associated genes are transcription factors, that would consequently 262 
perturb developmental transcriptional networks. Prior work has demonstrated 263 
differentiation to be impaired in Dnmt3a-deficient NPCs and hematopoietic stem cells 264 
(HSCs) with enhanced expression of multipotency/stem cell genes and decreases in 265 
differentiation/neurogenic gene transcripts 31,39,40. As W326R is a ‘gain of function’ 266 
mutation, we postulated that a reciprocal transcriptional phenotype would be evident 267 
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in Dnmt3aW326R/W326R NPCs. Accordingly, we examined two gene sets, representing 268 
genes that are respectively up and down-regulated during differentiation of mESCs 269 
to terminally-differentiated neurons38 (Fig. 5h).  In line with our expectation, 270 
Dnmt3aW326R/W326R NPCs demonstrated a transcriptional bias towards expression of 271 
neurogenic genes at the expense of genes normally expressed in the pluripotent 272 
state. This suggests that hypermethylation of DMV/DMRs could lead to a skewing of 273 
stem/progenitor cells towards differentiation away from self-renewal.  274 
  275 
Dnmt3aW326R/+ mice have reduced brain size and body weight 276 
Finally, we generated a Dnmt3aW326R/+ mouse using CRISPR/Cas9-mediated 277 
homology directed repair (Supplementary Fig. 9a,b) to provide an in vivo model. 278 
Recapitulating the patient growth restriction phenotype, Dnmt3aW326R/+ mice were 279 
viable, healthy and morphologically unremarkable, but were proportionately small 280 
with significantly reduced body and brain weight (Fig. 6a-c, Supplementary Fig 9c,d). 281 
Furthermore, bisulfite sequencing of cerebral cortex and liver provided in vivo 282 
confirmation of hypermethylation at polycomb-regulated regions, with substantial 283 
methylation observed at the Hoxc13 and Sox1 loci in Dnmt3aW326R/+ mice (Fig. 284 
6d,Supplementary Fig. 9e). Furthermore, RRBS analysis confirmed that genome-285 
wide, NPC hypermethylated DMRs were hypermethylated in the Dnmt3aW326R/+ 286 
mouse cortex (Supplementary Fig. 9f-h).  287 
 288 
Discussion 289 
Here we report widespread DNA hypermethylation at Polycomb-regulated regions 290 
resulting from a gain of function mutation in DNMT3A.  As such genomic regions 291 
contain key developmental genes, classical patterning defects might be expected, 292 
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but, surprisingly, the DNMT3AW330R mutation instead causes an extreme growth 293 
disorder. 294 
 295 
Unexpectedly our findings suggest that the DNMT3A PWWP domain limits DNA 296 
methylation at Polycomb-regulated regions. DNMT3A has been previously shown to 297 
counter H3K27 tri-methylation in vivo, with wild-type (but not catalytically dead) 298 
DNMT3A opposing PRC2 binding in neural stem cells31. In patient cells, it is 299 
therefore likely that altered binding specificity of DNMT3AW330R leads to it methylating 300 
polycomb-associated DMRs and DMVs, with a secondary reduction occurring in 301 
H3K27me3 due to impaired binding of PRC2 to methylated DNA30,31.  302 
Biochemically, binding to H3K36me2/3 is abrogated in the PWWPW330R mutant. How 303 
then could this impaired interaction with H3K36me2/3 connect with DNA methylation 304 
of H3K27me3 regions? We favour a model where widespread distribution of 305 
H3K36me2/3 leads to wild-type DNMT3A being targeted to many genomic sites and 306 
limiting its availability to non-preferred sites such as polycomb-associated regions 307 
(Fig 6e). Consistent with this model, we see low levels of H3K36me3 at DMRs and 308 
DMVs, explained by H3K36me2/3 rarely co-existing with H3K27me3 on histones32,33. 309 
As well, genome-wide, H3K36me3 is strongly anticorrelated with H3K27me3, and 310 
low levels of H3K36me2 correlated with increased H3K27me334. Furthermore, 311 
H3K36me2 is actively removed by KDM2A from unmethylated CpG regions41 and  312 
Nsd1-mediated H3K36me2 methylation has recently been shown to restrict 313 
deposition of H3K27me3 34. 314 
 315 
In our model we propose that disruption of PWWP-H3K36me2/3 interactions in 316 
patient cells would increase availability of DNMT3AW330R to interact with DNA in 317 
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polycomb regions (Fig 6e), increasing the possibility of DNA methylation, 318 
consequently impairing PRC2 binding and polycomb-domain integrity. Alternative 319 
explanations are also possible. For instance, the PWWPWT-H3K36me2/3 interaction 320 
may normally be required for enzymatic activity, whereas DNMT3AW330R may be 321 
permissive for DNA methylation without the interaction; or the PWWP domain may 322 
mediate non-histone interactions critical to restrict it from Polycomb-marked loci. 323 
Further studies, including assessment of DNMT3AW330R localization by ChIP-seq to 324 
determine genomic distribution, will be important in distinguishing between these 325 
possibilities. Nonetheless, our findings establish the DNMT3A PWWP domain as a 326 
factor countering methylation of key developmental loci, one that may act alongside 327 
Tet enzymes42,43 and FBXL1044 to ensure their hypomethylation.   328 
 329 
Previously identified microcephalic dwarfism genes impair cell proliferation to reduce 330 
cell number and organism size1, so how might this mutation in DNMT3A act?  Both 331 
DNA methyltransferases and Polycomb can impart heritable transcriptionally 332 
repressive epigenetic marks. However, while DNA promoter methylation is 333 
considered to stably silence genes45, Polycomb repression is potentially reversible, 334 
maintaining plasticity of gene expression and enabling robust switching to gene 335 
activation in response to developmental cues46,47. Dnmt3a loss in hematopoietic 336 
stem cells leads to expanded stem cell numbers at a cost to differentiated progeny39. 337 
Likewise, Dnmt3a null neural stem cells have markedly reduced neurogenic 338 
potential31. Conversely, loss of the PRC2 H3K27me3 methyltransferase, Ezh2, from 339 
cortical progenitors impairs self-renewal promoting premature neuronal 340 
differentiation48, and here we observe a transcriptional bias away from pluripotency 341 
towards differentiation in Dnmt3aW326R/W32R NPCs (Fig 5.). Hence, gain of function 342 
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DNMT3A mutations might increase cellular differentiation leading to premature 343 
depletion of stem/progenitor cell pools and reduce final cell numbers in tissues and 344 
consequently organism size (Supplementary Fig. 8d).  345 
 346 
Like DNMT3A, haploinsufficiency of H3K36 methyltransferases NSD1 and SETD2, 347 
cause macrocephalic overgrowth13,49,50. Mutations in genes encoding EZH2, and 348 
EED subunits of Polycomb complexes also cause overgrowth51-53 and PHC1 349 
mutation results in microcephalic dwarfism54. While DNA methylation and Polycomb-350 
repression are thought of as mutually antagonistic and exclusive processes at 351 
specific loci, our findings linking H3K27, H3K36 and DNA methylation, suggest a yet 352 
to be defined common developmental mechanism for these syndromes. 353 
Furthermore, given NSD1, DNMT3A and EZH2 are both height QTLs and 354 
somatically mutated in cancer55,56, the interplay between Polycomb and DNA 355 
methylation has wider relevance both to neoplastic processes and physiological 356 
regulation of human size, that warrants further investigation. 357 
 358 
Accession Codes: 359 
DNMT3A –NM_175629.2 360 
EGA: WES data: EGAS00001003231; RNAseq/RRBS/ChIPseq EGAS00001003232  361 
GEO: awaiting accession codes 362 
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Fig. 1| De novo mutations in DNMT3A cause microcephalic dwarfism.  524 
a, Schematic of DNMT3A protein and domains.  Position of microcephalic dwarfism 525 
(MD) mutations (red) and Tatton-Brown-Rahman syndrome (TBRS) overgrowth 526 
(grey) mutations (Tatton-Brown et al. 2014) (MTase, DNA methyltransferase domain) 527 
b, The heterozygous de novo c.988T>C mutation results in substitution of a 528 
Tryptophan residue (patient 1 and 2). The heterozygous de novo c.997G>A mutation 529 
results in substitution of an Aspartic acid residue (patient 3). Both residues are 530 
conserved in vertebrates c, and replaced with a physiochemically dissimilar residue: 531 
Arginine (p.W330R) and Asparagine (p.D333N) respectively.  Sequence alignments, 532 
Clustal Omega. d, The W330R and D333N mutations cause extreme growth failure 533 
and microcephaly (red diamonds, n=3 independent patients), in direct contrast to 534 
DNMT3A overgrowth patients (grey circles, n=13 and n=12 patients, respectively for 535 
height and OFC). Height and head circumference (OFC) plotted as z-scores (s.d. for 536 
population mean adjusted for age and sex). Dashed lines at -2 and +2 s.d indicate 537 
95% confidence interval for general population. Horizontal bars, mean values for 538 
respective patient groups. TBRS morphometric data reproduced from Tatton-Brown 539 
et al. 201411. 540 
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Fig. 2| The W330R mutation impairs binding of di/tri-methylated H3K36.  542 
a, Murine Dnmt3aW326R protein, containing the orthologous substitution to W330R, is 543 
stably expressed, in contrast to corresponding overgrowth PWWP mutations 544 
(W293del, I306N).  Immunoblotting of cell lysates from CRISPR/Cas9 genome-545 
edited mouse embryonic stem cells (mESC). Multiple independent cell lines, with 546 
genotypes as indicated. Representative of n=3 (WT, W326R lines) and n=2 547 
(W293del, I306N) independent experiments. Immunoblots are cropped.  b, Structural 548 
modelling of the PWWP domain predicts the W330R mutation to disrupt interaction 549 
with H3K36me3. The highlighted amino acids (blue) form a cage that binds 550 
trimethylated lysine 36 (purple). The amino acids altered in MD patients (tryptophan 551 
at codon 330 and aspartate at codon 333) are labelled in red. Backbones of PWWP 552 
and histone H3 N-terminal tail depicted in grey and pink respectively. c,d, 553 
Recombinant PWWPWT but not PWWPW330R protein binds H3K36me3 peptide. (c) 554 
Schematic of streptavidin pull-down of biotinylated histone peptides. (d) Coomassie 555 
stained gel of eluted protein from histone peptide pull-downs (cropped).  Input, 9% of 556 
total protein. Histone peptide H3 (aa 21-44). H3K36me0 corresponding unmodified 557 
peptide. Representative of n=3 expts. e, PWWPW330R does not bind H3K36me2, 558 
H3K36me3 or other histone-tail modifications. MODified™ Histone Peptide Array 559 
representing 384 distinct or combinatorial histone modifications probed with 560 
recombinant PWWP proteins as indicated. Below, magnified insets of row L7-11 561 
(histone 3 aa26-45) and K1-3 (histone 3 aa16-35) demonstrates that PWWPWT binds 562 
to H3K36me2 (L9) and H3K36me3 (L10), but PWWPW330R does not. Representative 563 
of n = 2 independent expts; see also Supplementary Fig. 1b. 564 
 565 
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Fig. 3| DNA methylation is increased at key developmental gene loci in patient 567 
cells. 568 
a, DNA methylation in DNMT3AW330R/+ patient fibroblasts significantly differs from 569 
controls. Unsupervised Ward clustering based on Pearson correlations of all probes 570 
from Illumina EPIC arrays for n=2 independent patients and 2 independent controls. 571 
Pvclust, approximately-unbiased p-values using 1000 bootstraps. b,c, A methylation 572 
signature is evident in DNMT3AW330R patient cells across tissues, comprising 1140 573 
sites of increased methylation. (b) Heat map of differentially methylated regions 574 
(DMRs) hypermethylated in patient fibroblasts and peripheral blood leukocytes 575 
(PBLs). P1, P2, patients (DNMT3AW330R/+); C1-C4 healthy controls; O1, O2, TBRS 576 
overgrowth patients. (c) Quantification of DNA methylation for DMRs (n=1140 577 
DMRs) depicted in panel (b). Box, 25th-75th percentile; whiskers, full data range; 578 
centre line, median; ∆%mCpG, percent change of methylation relative to mean of 579 
control. p value, two-sided, paired Wilcoxon rank sum tests for mean of control 580 
probes vs mean patient probes. d, Gene ontology analysis of genes associated with 581 
hypermethylated DMRs. Top ten significant hits shown. Color indicates Benjamini-582 
Hochberg adjusted FDR significance level, genes associated with DMR probes 583 
(n=907 genes) versus genes associated with all probes on the array (n=18159), two-584 
sided Fisher’s exact test. e, Exemplars of DNA binding factors and morphogens 585 
associated with DMRs. f, Representative genome browser views of hypermethylated 586 
DMRs demonstrating increased DNA methylation at key developmental genes in 587 
microcephalic dwarfism patient samples. All tracks scaled 0-100% mCpG, DNA 588 
methylation. CGI, CpG islands. 589 
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Fig. 4| DNA methylation is increased at polycomb-marked DNA methylation 591 
valleys.  592 
a, Hypermethylated DMRs in DNMT3AW330R patient cells are significantly enriched at 593 
poised promoters and polycomb-repressed regions. Plotted, enrichment of chromatin 594 
state categories as identified in normal human lung fibroblasts (NHLF) by 595 
ChromHMM in patient hypermethylated DMRs. P-values for each enriched category, 596 
two-sided Fisher’s exact test hyper-DMR probes (n=10871 probes) vs all probes 597 
(n=403348). (ChromHMM: software annotating Chromatin state by a Hidden Markov 598 
Model)57. b-d, H3K27me3 sites in control dermal fibroblasts correlate with 599 
hypermethylated DMRs in patient cells. (b) Heat map of normalised H3K27me3 600 
ChIP-seq reads in control fibroblasts (mean of C1, C2) centred on DMRs, ranked by 601 
DMR mean H3K27me3 levels. Scale indicates normalised read counts. Window size, 602 
250 bp. (c,d) Quantification of H3K27me3 enrichment at hypermethylated DMRs. (c) 603 
Percentage of Infinium array probes overlapping H3K27me3 peaks in control 604 
fibroblasts (red, mean of C1 and C2). All, all probes on the array (n=403348 probes). 605 
Hyper-DMRs, probes within hypermethylated DMRs (n=10871). p-value, two-sided 606 
Fisher’s exact test. (d) Venn diagram displaying overlap of hypermethylated DMRs 607 
(n=1140) with H3K27me3 peaks (n=3815) in controls. p value, two-sided Fisher’s 608 
exact test. (e) Genes associated with hypermethylated DMRs (n=907 genes), 609 
significantly overlap genes associated with DMVs (n=1,358). Two-sided Fisher’s 610 
exact test, genes associated with hyper-DMRs vs all genes represented on array. (f) 611 
Increased methylation is distributed across H3K27me3 regions, but excluded from 612 
H3K4me3 peaks. Representative IGV genome browser views. For all tracks: DNA 613 
methylation (magenta, scale 0-100%), H3K27me3 (green, scale 0-4 scaled read 614 
counts per 107 reads), H3K4me3 (yellow, scale 0-8 scaled read counts per 107 615 
reads) in control (C1, C2) and patient (P1, P2) dermal fibroblasts. DNA methylation 616 
data for SOX1 and FOXA1 (Fig. 3f) are shown again for comparison with H3K27me3 617 
and H3K4me3. g, Polycomb-marked DNA methylation valleys (DMVs) are 618 
hypermethylated in DNMT3AW330R/+ patients.  Shown, heat maps of n=1,152 DMVs26 619 
of normalised H3K27me3/K4me3 read counts for control (C1,C2 mean) and patient 620 
(P1,P2 mean) fibroblasts, centred on DMVs and ranked by mean H3K27me3 levels 621 
in controls. ∆%mCpG, percent change of DMV methylation relative to mean of 622 
controls. Window size, 500bp. h, i, Quantification of data shown in panel g. (h) 623 
Polycomb-marked DMVs exhibit increased methylation in patient cells, while non-624 
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polycomb associated regions do not. Y-axis indicates mean difference between 625 
patients and controls: 0, no change; >0 increased in patients; <0 decreased in 626 
patients. (i) Polycomb-marked DMVs with increased methylation in patient cells, 627 
exhibit lower levels of H3K4me3 in controls (C1, C2 mean). Box, 25th-75th percentile; 628 
(h) whiskers, full data range; (i) whiskers, 1.5x interquartile range; centre line, 629 
median. Polycomb marked DMV definition, see methods. (p-values in h,i, two-sided 630 
Wilcoxon rank sum tests, polycomb positive (+) (n=524) versus negative (-) (n=628) 631 
DMVs).  632 
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Fig. 5| Hypermethylation of polycomb-marked regions is observed on 634 
differentiation of Dnmt3aW326R pluripotent stem cells.  635 
a-e, DNA methylation at DMRs occurs during cellular differentiation to embryoid 636 
bodies (EBs) and neural progenitor cells (NPCs) in CRISPR/Cas9-edited 637 
Dnmt3aW326R mESCs. Bisulfite sequencing of the Hoxc13 locus of (a) LIF/serum 638 
maintained mESCs, (b) after 9 days differentiation to EBs and (c) after 9 days neural 639 
induction to NPCs. For EBs and NPC differentiation, representative of n=2 640 
independent experiments each. Blocks, independent cell lines; open and closed 641 
circles, unmethylated and methylated CpGs, respectively; dots, undetermined 642 
methylation status; columns CpG sites; rows individual sequences. Total percentage 643 
methylation calculated per sample. (d) Genome browser view of RRBS DNA 644 
methylation profiles after 9 days neural differentiation. Tracks, independent wild type 645 
(dark grey), and Dnmt3aW326R (blue) cell lines. Neural precursor cell H3K27me3 data 646 
(magenta) from published ChIP-seq dataset38. DNA methylation (scale 0-80%, all 647 
tracks). (e) Hypermethylated DMRs are enriched for H3K27me3 peaks in wildtype 648 
NPCs.  Percentage of CpGs observed in RRBS overlapping with H3K27me3 peaks. 649 
H3K27me3 data from wild type NPC ChIP-seq dataset38. All, all CpGs observed 650 
(n=1178718 CpGs). Hyper-DMRs, CpGs within hypermethylated DMRs (3117). P-651 
value, two-sided Fisher’s exact test. f, Hypermethylated gene loci in Dnmt3aW326R 652 
NPCs substantially overlap those in patient cells. Venn diagram of orthologous 653 
genes (human n=781; mouse n=207) associated with respective DMRs. P-value, 654 
two-sided Fisher’s exact test. (g) Reduced expression for genes associated with 655 
hyper-DMRs is evident during NPC differentiation. RNA-seq data for NPC 656 
differentiation experiment from panel d. (n=3 wild-type clones, n=3 657 
Dnmt3aW326R/W326R clones). log2 CPM ratios of Dnmt3aW326R/W326R versus wildtype at 658 
9 day NPC differentiation plotted. Box, 25th-75th percentile; whiskers, 1.5x 659 
interquartile range from box; centre line, median. Two-sided Wilcoxon rank sum test, 660 
All genes with coverage in RRBS (n=12620 genes) vs genes associated with hypo-661 
DMRs (n=169) or hyper-DMRs (n=161). h-i, Neurogenic gene transcription bias in 662 
Dnmt3aW326R/W326R NPCs. (h) log2 CPM ratios of genes for Dnmt3aW326R/W326R versus 663 
wild-type 9 day-differentiated NPCs.  All, all genes n=13,022; and gene sets, 664 
upregulated (n=3,864 genes), unchanged (n=3,516) and downregulated genes 665 
(n=3,281) during differentiation from mESCs to neurons. Box, 25th-75th percentile; 666 
whiskers, 1.5x interquartile range from box; centre line, median. Two-sided Wilcoxon 667 
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rank sum test, log2 W326R/WT for All vs up or downregulated gene sets. (i) 668 
Schematic: Gene sets defined on basis of published dataset of mESC differentiation 669 
to terminally differentiated neurons38.  Downregulated and upregulated gene sets 670 
defined as those genes with reduced and increased transcripts respectively in 671 
neurons relative to ES cells. The downregulated set therefore contains pluripotency-672 
related genes (light blue) and the upregulated set, neuronal differentiation genes 673 
(light red). 674 
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Fig. 6| Dnmt3aW326R/+ mice have reduced brain size and body weight, alongside 676 
hypermethylation of developmental genes.  677 
a, 10-week old Dnmt3aW326R/+ mouse next to wild-type littermate. (b) Body weight for 678 
6 week-old Dnmt3aW326R/+ mice compared to wild type littermates. Males, n=14 679 
wildtype and n=18 Dnmt3aW326R/+ animals. Females, n= 16 wildtype and n=23 680 
Dnmt3aW326R/+ animals. (c) Brain weight of female Dnmt3aW326R/+ mice compared to 681 
wild type litter mates at 5 months of age. n=7 wildtype and 9 Dnmt3aW326R/+ animals. 682 
h,i P-values, two-tailed t-test. Horizontal bar, mean weight per group. (d) Locus-683 
specific (Hoxc13) bisulfite sequencing for cortex and liver samples from 684 
Dnmt3aW326R/+ and wild-type littermates (n=3/group; female, age 8 weeks). e, 685 
Proposed model linking disruption of the H3K36me2/3<--> PWWP interaction with 686 
DMV DNA methylation.  WT-DNMT3A is normally targeted to H3K36me2 and 687 
H3K36me3, marks present widely in the genome32,58, but rarely coexist with 688 
H3K27me3 32,33. This limits availability of free-DNMT3A to bind at other locations. 689 
When the PWWP-H3K36me2/3 interaction is disrupted, sufficient free DNMT3A is 690 
available to methylate genomic DNA at DMVs. Enzymatic activity of DNMT3A and 691 
DNA methylation impair PRC2 chromatin binding30,31, leading to secondary loss of 692 
H3K27me3. Notably, the long isoform of DNMT3A (DNMT3A1) localises to the edge 693 
of Polycomb domains21,43. When mutated it is therefore well placed to methylate 694 
these regions. DNMT3A1 is also the major isoform expressed after ESC 695 
differentiation21, potentially explaining timing of hypermethylation. Filled circles 696 
methylated CpG, open circles unmethylated CpG. Diamonds, H3K36me2/3 modified 697 
histones. 698 
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Materials and Methods 700 
 701 
Research subjects 702 
Genomic DNA from affected children and family members was extracted using 703 
standard protocols. Informed, written consent was obtained from all participating 704 
families. The study was approved by the Scottish Multicentre Research Ethics 705 
Committee (04:MRE00/19) and the Institutional Review Board of Cincinnati 706 
Children's Hospital Medical Center (Protocol#2014-5919). All relevant ethical 707 
regulations were followed. Genotypes of TBRS patients were as follows: O1: 708 
DNMT3A – heterozygous c.1936G>C p.Gly464Arg; O2: DNMT3A – heterozygous 709 
c.2086del p.Gln696ArgFsTer9. 710 
 711 
Exome sequencing  712 
Exome sequencing of patients 1 and 3 was performed by Edinburgh Genomics and 713 
Cincinnati Children's Hospital Sequencing Core Facility respectively as described 714 
previously59,60. Patient 2 was sequenced by Illumina MiSeq using a custom targeted 715 
capture (SureSelect, Agilent Technologies) targeting DNMT3A and other primordial 716 
dwarfism/microcephaly genes. Confirmatory Sanger sequencing was performed on 717 
all affected individuals and their parents. Primers listed in Supplementary Table 6. 718 
Further details see Supplementary Note. 719 
 720 
Cell culture  721 
Primary fibroblast cell lines were maintained at 3% O2 in Dulbecco’s modified 722 
Eagle’s medium (DMEM; Life Technologies) supplemented with 10% FBS and 5% 723 
penicillin-streptomycin antibiotics or in AmnioMAX-C100 (Life Technologies). HeLa 724 
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cells, a kind gift from G. Stewart (Birmingham) originally obtained from ATCC, were 725 
maintained in Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies) 726 
supplemented with 10% FBS and 5% penicillin-streptomycin antibiotics. E14 Tg2a IV 727 
mESCs were cultured on 0.1% gelatine coated dishes and maintained in Glasgow's 728 
Minimum Essential Medium (GMEM; Life Technologies) supplemented with 10% 729 
FBS (HyClone), 1 mM Sodium Pyruvate (Sigma); 1x MEM non-essential amino acids 730 
(Sigma), 2 mM L-Glutamine, 5% penicillin-streptomycin antibiotics, 0.001% β-731 
mercaptoethanol (Sigma) and leukemia inhibitory factor. Details for differentiation 732 
protocols see Supplementary Note. 733 
 734 
Generation of CRISPR/Cas9 edited mESCs 735 
Guide RNAs were designed using the optimized CRISPR design webtool 736 
(http://crispr.mit.edu/) with corresponding oligonucleotides cloned into pSpCas9(BB)-737 
2A-GFP or pSpCas9n(BB)-2A-GFP (kind gift from Feng Zhang, Addgene Plasmids 738 
pX458:#48138, pX461:#48140)14. ssDNA oligonucleotides (ssODN, IDT Ultramers) 739 
repair template sequences for homology directed repair listed in Supplementary 740 
Table 6. Two independent CRISPR/Cas9 strategies were employed to generate the 741 
W326R mutation in the clones used in this study: each using different gRNAs, and 742 
either Cas9-nickase (nCas9) or wildtype Cas9 respectively. Vectors containing guide 743 
RNA sequences were transfected together with single stranded DNA 744 
oligonucleotides using FuGENE HD transfection reagent (Promega). GFP-positive 745 
cells were selected by FACS (FACSAriaII, FACSDiva Software Version 6.1.3, 746 
Becton-Dickinson) 48 hours after transfection and plated at clonal density. Individual 747 
colonies were grown up and validated by Sanger sequencing.  748 
 749 
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Immunoblot analysis and antibodies 750 
Whole cell extracts for mESCs, human primary Fibroblasts and HeLa cells were 751 
obtained by sonication in UTB buffer (8 M urea, 50 mM Tris, pH 7.5, 150 mM β-752 
mercaptoethanol) and analyzed by SDS-PAGE using 4–12% NuPage Bis-Tris 753 
Protein gels (Life Technologies) and transferred onto nitrocellulose membrane. 754 
Immunoblotting was performed using antibodies to Dnmt3a (Novus Biologicals 755 
NB120-13888; 1:500), EZH2 (Cell Signaling #5246S; 1:1000) and Actin (Sigma 756 
A2066; 1:5000). Images acquired with ImageQuant LAS 4000. Uncropped images in 757 
Supplementary Fig. 11. 758 
 759 
RNA interference 760 
EZH2 was targeted with 40nM of an ON-TARGETplus Human siRNA SMARTpool 761 
(L-004218-00-0005, Dharmacon) and cells harvested 48 hours after transfection with 762 
RNAiMAX (Thermo Fisher). 763 
 764 
RT-PCR and RNA-sequencing 765 
RNA was extracted using the RNeasy kit (QIAGEN) according to manufacturer 766 
instructions with DNAseI (QIAGEN) treatment. For RT-PCR cDNA was generated 767 
using SuperScript III Reverse Transcriptase (Invitrogen) and random primers 768 
(Promega). Primers for RT-PCR listed in Supplementary Table 6. 769 
For RNA-sequencing, random primed cDNA from poly-A selected RNA was 770 
converted into an Illumina sequencing library and single-end 50bp reads generated 771 
on an Illumina HiSeq machine (GATC Biotech Konstanz, Germany). 772 
RNA-seq data were aligned to the genome using bowtie 2 (v2.3.1). Further data 773 
processing details see Supplementary Note. Alignment statistics are provided in 774 
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Supplementary Table 7 and summaries of the data are shown in Supplementary Fig. 775 
8a,b. 776 
 777 
Structural Modelling 778 
The impact of W330R on the interaction with H3K36me3 was modelled with FoldX61 779 
using the crystal structure of the DNMT3B PWWP domain bound to H3K36me3 780 
(PDB ID: 5CIU). The change in interaction energy caused by the equivalent W263R 781 
mutation in DNMT3B was calculated with the AnalyseComplex function. Since the 782 
H3K36me3 binding site is highly conserved between DNMT3A and DNMT3B, 783 
including full conservation of all the aromatic residues involved in binding highlighted 784 
in Figure 2, this suggests that W330R would also disrupt the interaction. 785 
 786 
Generation of recombinant PWWP protein 787 
PWWP domain of DNMT3A was expressed in E.coli and purified using standard 788 
methods, documented in the Supplementary Note.  789 
 790 
Histone peptide pull downs 791 
20 µg of purified recombinant GST-PWWP fusion protein and 2000 pmol of histone 792 
H3 biotinylated peptides (AnaSpec peptides; AS-64440 and AS-64441) were diluted 793 
in interaction buffer (50 mM Tris/HCl pH8.0, 100 mM NaCl, 2 mM EDTA, 0.1% Triton 794 
X-100 freshly supplemented with 0.5 mM DTT, 0.2 mM PMSF and 1x protease 795 
inhibitor cocktail, Roche)15. Reactions were incubated overnight under rotation at 796 
4°C. MyOne T1 streptavidin beads (Life Technologies) were added to the reactions 797 
and rotated for 4h at 4°C, followed by three washes with interaction buffer. 20 µl of 798 
sample loading buffer (50 mM Tris pH6.8, 20% Glycerol, 20% SDS, 625 mM β-799 
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mercaptoethanol, bromphenolblue) were added to beads, boiled for 5 min and eluted 800 
proteins separated on 15% SDS-PAGE and visualised with Coomassie Blue R250. 801 
 802 
Peptide arrays 803 
Peptide arrays were processed following manufacturer instructions for the MODified 804 
Histone Peptide Arrays (Active Motif). In brief, arrays were blocked and washed with 805 
buffers provided. 10nM or 100nM wildtype or W330R DNMT3A GST-tagged PWWP 806 
protein was diluted in interaction buffer (100 mM KCl, 20 mM Hepes pH7.5, 1 mM 807 
EDTA, 0.1 mM DTT, 10% glycerol)15 and incubated overnight at 4°C on an orbital 808 
shaker. Protein-peptide interactions were detected with an antibody directed against 809 
the GST-tag (GE Healthcare 27-4577-01; 1:5000) with subsequent ECL-based 810 
detection. c-Myc mouse monoclonal antibody (1:2000, Active-Motif). Images 811 
acquired using ImageQuant LAS 4000. 812 
 813 
Infinium® MethylationEPIC BeadChip 814 
Fibroblast genomic DNA extracted using the DNeasy Blood & Tissue Kit (QIAGEN). 815 
DNA was bisulfite converted using the EZ DNA Methylation kit (Zymo Research, 816 
Infinium assay protocol).  Infinium® MethylationEPIC BeadChip performed according 817 
to manufacturer instructions by Edinburgh WTCRF. The Bioconducter package minfi 818 
(v1.22.1) was used to process raw Infinium idat files (ssNoob method)62,63. For 819 
further details, see Supplementary Note. Overall summaries of Infinium methylation 820 
data are shown in Supplementary Figure 10a,b and d. 821 
 822 
Chromatin immunoprecipitation and sequencing 823 
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Cross-linked chromatin immunoprecipitation was adapted from previous publications 824 
64,65 , further detailed in the Supplementary Note. For H3K27me3 single-end 50bp 825 
reads were generated on an Illumina HiSeq machine (GATC Biotech Konstanz, 826 
Germany). For H3K4me3, H3K36me3 ChIP-Rx and H3K27me3 ChIP-Rx single-end 827 
75bp reads were generated on an Illumina NextSeq 550 machine (WTCRF 828 
Edinburgh, UK). 829 
ChIP-seq read quality assessment and alignment was performed as for RNA-seq. 830 
For ChIP Rx-seq, reads were aligned to a combination of the hg19 and dm6 831 
genomes using the same settings. Multi-mapping reads excluded as for RNA-seq. 832 
Additionally, PCR duplicates excluded using SAMBAMBA (v0.5.9)66. Sequencing 833 
statistics are shown in Supplementary Table 8. For further analysis details see 834 
Supplementary Note.  835 
 836 
Histone acid extraction and histone PTM detection by mass spectrometry 837 
Histones were acid extracted as previously described32 with minor modifications and 838 
LC MS/MS analyses were performed on an Orbitrap Fusion Lumos coupled to 839 
Dionex Ultimate3000RSLCnano UHPLC system. For further details see 840 
Supplementary Note.  841 
 842 
Bisulfite PCR sequencing 843 
Genomic DNA was isolated using the DNeasy Blood & Tissue Kit (QIAGEN) or 844 
Phenol-Chloroform extraction. 250-500ng DNA was bisulfite converted with the EZ 845 
DNA Methylation-Lightning Kit (Zymo Research) according to manufacturer 846 
instructions. Converted DNA was eluted twice in 10 µl elution buffer. Bisulfite PCR 847 
primer sequences provided in Supplementary Table 6. Products were amplified 848 
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using FastStart PCR Master Mix (Roche), purified using the QIAquick PCR 849 
purification Kit (QIAGEN) and subcloned into pGEMT-easy (Promega). Individual 850 
bacterial colonies were sanger sequenced using M13 sequencing primers, analysed 851 
using BISMA67 and results formatted with the BiQ Analyzer Diagrams tool68. In two 852 
independent experiments of NPC/EB differentiation, the following cell lines were 853 
used: For EB experiments: WT3, hom2 (n=2); WT1, hom3, het (n=1). For NPC, 854 
WT1, hom2, hom3, het (n=2); WT2,WT3, hom1 (n=1).  855 
 856 
Reduced Representation Bisulfite Sequencing (RRBS) 857 
Genomic DNA isolated with DNeasy Blood & Tissue Kit (QIAGEN) or Nucleon 858 
BACC2 Genomic DNA Extraction Kit (illustra) and quantified by Qubit (Invitrogen). 859 
DNA from mouse cortex samples were concentrated using Agencourt AMPure XP 860 
technology. 200ng of purified DNA samples (for NPC differentiation: DNA from 861 
experiment depicted in Fig.5c; for mouse cortexes in Fig. 6d, Supplementary Fig. 9e) 862 
were processed using the Ovation RRBS Methyl-Seq system kit (NuGen 863 
Technologies) according to instructions with modifications documented in the 864 
Supplementary Note. RRBS sequencing was aligned and processed using Bismark 865 
(v0.16.3)69.  866 
 867 
Processed RRBS files were assessed for conversion efficiency based on the 868 
proportion of methylated reads mapping to the λ genome spike-in (>99.5% in all 869 
cases, Supplementary Table 9) and processed in R to call DMRs. Alignment 870 
statistics provided in Supplementary Table 9. BigWigs were generated from RRBS 871 
data using CpGs with coverage ≥5. BigWigs for Patient 3 and Control 3 were 872 
generated only from CpGs with coverage ≥5 in both samples to facilitate visual 873 
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comparison (shown Figure S3d). Overall summaries of RRBS data are shown in 874 
Figure S10c, f-h. Mean methylation in each sample was calculated as the weighted 875 
mean across all CpGs observed on autosomes irrespective of coverage (methylated 876 
coverage/total coverage). 877 
 878 
Generation of Dnmt3aW326R mice 879 
A template for in vitro transcription was prepared by PCR, using the pX458-based 880 
plasmid containing the Dnmt3a-targeting gRNA sequence, a T7-tagged gRNA 881 
specific forward primer and a universal reverse primer (sequences Supplementary 882 
Table 6), PCR product purified by QIAquick PCR Purification (QIAGEN) and gRNA 883 
was produced by in vitro transcription (NEB HiScribe T7 High Yield RNA Synthesis 884 
Kit) using 1 µg of PCR product, and purified using the RNeasy Mini Kit (QIAGEN). 885 
Transgenic mice were generated by cytoplasmic injection of gRNA (25 ng/µl), Cas9 886 
mRNA (50 ng/µl; L-6125; TriLink Biotechnologies) and ssODN repair template (150 887 
ng/µl) into B6CBAF1/J single cell embryos. All resulting pups were screened by PCR 888 
amplification and sanger sequencing of the targeted region (primer sequences, 889 
Supplementary Table 6). F0 males were crossed with CD-1 females to establish 890 
germline transmission. F1 Dnmt3aW326R/+ males were crossed with CD-1 females 891 
and F2 offspring used for phenotyping and tissue collection (investigators were 892 
blinded to genotypes). Mouse studies were approved by the University of Edinburgh 893 
animal welfare and ethical review board (AWERB) and conducted according to UK 894 
Home Office regulations under a UK Home Office project license. 895 
 896 
Statistical analysis 897 
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Statistical testing was performed using R v3.4.2 and GraphPad PRISM 6. Tests used 898 
indicated in figure legends. All tests were two-sided, unless otherwise stated. Further 899 
details of specific analyses provided in the relevant methods sections, below and 900 
Supplementary Note.  901 
 902 
Hierarchical clustering 903 
Clustering was performed on processed Infinium Beta probe values using R 904 
(Pearson correlation distance and Ward method). Cluster significance was tested 905 
using the CRAN package ‘pvclust’ (v2.0.0).  906 
 907 
Differentially methylated region identification 908 
Windows of 5 contiguous probes or CpGs were used to identify DMRs for Infinium 909 
and RRBS data respectively. For Infinium arrays DMRs were called on the basis of 910 
≥3 probes in a window having a difference in Beta value of at least 0.1 between each 911 
individual patient sample and each of the two control fibroblast lines, changed in the 912 
same direction, and with no CpG ≥1000bp from its neighbours in the window. For 913 
this analysis we also only considered probes showing the same difference in both 914 
the patient 1 replicates. Overlapping or contiguous DMR windows were merged.  For 915 
enrichment analyses, the set of DMR probes was compared to a genome-wide 916 
background control set of ‘All’ probes, derived from genomic regions spanning 917 
genomically-contiguous probes that fulfilled the same distance threshold criteria (ie. 918 
CpG ≤1000bp from neighbours). DMR methylation level, defined as the mean Beta 919 
value of all probes located in the DMR. Fibroblast DMRs are provided in 920 
Supplementary Tables 2 and 3. 921 
 922 
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For RRBS data DMRs were called using a binomial linear model to test for a 923 
difference in the proportion of methylated reads for each CpG in the homozygous 924 
mutant samples versus controls. CpGs showing significant differences were then 925 
identified as those with Benjami-Hochberg adjusted p-values <0.05. DMRs were 926 
then called in a manner similar to that used for the Infinium arrays but using a 927 
distance threshold of 200bp. A control set of CpG sites that were within the distance 928 
threshold was used as a background control set of ‘All’ CpGs for enrichment 929 
analyses. Only CpGs where coverage was ≥10 in all samples were considered for 930 
DMR calling (1,516,046 CpGs). For RRBS DMR methylation level was defined as 931 
the weighted mean methylation level (methylated coverage/total coverage) from all 932 
CpGs observed within the DMR region irrespective of coverage. NPC DMRs are 933 
provided in Supplementary Tables 5 and 10. 934 
 935 
 936 
Enrichment of DMRs in ChromHMM segmentations 937 
Infinium probes were mapped to existing ChromHMM annotations70 using the 938 
BEDtools intersect function (v2.27.1)71. Identical ChromHMM labels were merged for 939 
analysis. To test for enrichment of an annotation, a Fisher’s exact test was 940 
performed for number of DMR probes against number of control probes. 941 
 942 
DNA methylation valley analysis 943 
Previously reported DMVs26 were mapped to hg19 using the UCSC liftover tool and 944 
merged DMV regions from all 5 cell-types determined using the Bedtools merge 945 
function. DMV methylation level, defined as mean Beta value of all probes present in 946 
the DMV.  DMVs were then mapped to their closest genes using ChIPpeakAnno 947 
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(details Supplementary Note). Using DMR and control gene lists (as defined in GO 948 
analysis section), DMR enrichment at DMVs was tested by Fisher’s exact test, 949 
comparing the proportion of DMR-associated genes that were DMV genes with the 950 
proportion of control genes that were DMV genes. 951 
  952 
Analysis of histone modifications at DMRs, DMVs and ChIP-seq peaks 953 
Non-overlapping windows of 250bp (for DMRs and ChIP-seq peaks) or 500bp (for 954 
DMVs) were defined centred on each region of interest, with ChIP-seq read 955 
counts/window calculated using BEDtools’ coverage function. Read counts were 956 
scaled to counts per 10 million based on total number of mapped reads/sample and 957 
divided by the input read count to provide a normalised read counts. To prevent 958 
windows with zero reads in the input sample generating a normalised count of 959 
infinity, an offset of 0.5 was added all windows prior to scaling and input 960 
normalisation. Regions where coverage was 0 in all samples were removed from the 961 
analysis. ChIP-Rx was analysed similarly before samples were scaled using a 962 
normalisation factor generated from the number of reads mapping to the spike-in 963 
Drosophila genome. Reads mapping to the Drosphila genome in each ChIP and 964 
input sample were first scaled to reads per 1x107. The scaling factor was then 965 
calculated as the ratio of the scaled Drosophila reads in two ChIP samples over their 966 
respective ratio from the input samples, ie scaling factor, S, for sample n compared 967 
to reference sample ref: Sn=(dRPTMChIP-n/dRPTMChIP-ref)/(dRPTMIN-n/dRPTMIN-ref), 968 
where dRPTM = Drosophila Reads per 1x107 for ChIP and input, IN, runs 969 
respectively (modified from published method to take account of the presence of an 970 
input sample)65. To statistically test differences in histone modification levels, 971 
normalised read depths across DMRs/DMVs were compared using a Wilcoxon rank 972 
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sum test. H3K27me3-marked DMVs defined as those containing a H3K27me3 ChIP-973 
seq peak replicated in both control fibroblast lines. H3K27me3 and H3K4me3 peaks 974 
used for quantitative analysis were defined by merging peaks called in the two 975 
controls (using Bedtools merge). Only autosomal peaks overlapping those called in 976 
both control samples and containing Infinium probes in the background control set 977 
from DMR calling were used for analysis. The subsets of these peaks overlapping 978 
DMRs were defined using Bedtools intersect. The change in histone modification 979 
levels within regions of interest was defined as the log2 ratio of the mean mutant 980 
normalised read count over control normalised read count. The profile of H3K36me3 981 
at DMVs was generated by calculating normalised read counts in 10 scaled windows 982 
across DMVs together with 500bp windows extending 10Kb up- and down-stream of 983 
each DMV. Colour scales for ChIP-seq heatmaps range from the minimum to the 984 
90% quantile of the normalised read count for the reference dataset in each set of 985 
heatmaps.  986 
 987 
Analysis of enrichment of histone modifications at DMRs  988 
BEDtools intersect was used to overlap DMR probes with histone modification 989 
peaks. % DMR probes mapping to peaks was tested against % background control 990 
probes mapping to peaks using a Fishers exact test. A similar strategy was applied 991 
for mouse RRBS DMRs, testing DMR CpG versus background control CpG sites. 992 
 993 
RNAseq analysis 994 
To analyse RNAseq, the number of reads mapping to each ENSEMBL annotated 995 
gene (human: Release 75/GCRh37, mouse: Release 91/mm10) was calculated 996 
using the featureCounts module of the subread aligner (v1.5.2)72. Only reads 997 
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mapping to exons were considered. Gene read counts were then analysed using 998 
EdgeR (v3.18.1)73 with Trimmed Mean of M-values (TMM) normalization74. The log2 999 
normalised counts per million (CPM) and log2 ratios calculated by EdgeR were then 1000 
subject to further analysis. Only genes where CPM was >1 in ≥2 samples and that 1001 
are annotated as protein coding in ENSEMBL were considered for analysis (human 1002 
fibroblasts, 11,963 genes; mouse NPCs, 13,022 genes). To generate lists of genes 1003 
differentially regulated in published data of mES cells differentiated to terminally 1004 
differentiated neurons38, similar pre-processing was applied (resulting in data for 1005 
14,780 genes). Differential expression was then called using an F-test of a 1006 
generalised linear model fitted to the data taking account of sample batch using 1007 
EdgeR. Up and down regulated genes were called as those with Benjamini-1008 
Hochberg corrected FDR < 0.01 and a log-fold change >|1| (4,147 and 4,067 genes 1009 
respectively). Genes unchanged in the analysis were defined as those with 1010 
Benjamini-Hochberg corrected FDR > 0.05 (4,067 genes). 1011 
 1012 
Reporting Summary 1013 
Further information on experimental design is available in the Reporting Summary. 1014 
 1015 
Data availability 1017 
The human next-generation sequencing data used in the manuscript are available on 1018 
request from the relevant Data Access Committee from the European Genome–1019 
Phenome Archive (EGA). The exome data is available under the accession 1020 
EGAS00001003231. Human RNA-seq, RRBS and ChIP-seq under the accession 1021 
EGAS00001003232. The data are not publicly available to ensure protection of 1022 
patient sequence data confidentiality through controlled access. Processed data files 1023 
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and mouse RNA-seq/RRBS are available in GEO under accession (awaiting 1024 
accession number). 1025 
 1026 
 1027 
  1028 
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